Yahoo! News reaches 44.5 million monthly visitors and syndicated this in-depth GlobalData analysis. The article positions Helio alongside emerging immunotherapy trials, framing the company's diagnostic technology as a critical enabler for the next generation of liver cancer treatment.
This syndicated GlobalData article examines how Helio Genomics' blood-based test detects tumor-associated epigenetic signals in cell-free DNA alongside protein biomarkers. It reports that five-year survival for liver cancer drops from 37% for localized disease to just 3% for distant disease, underscoring the urgent need for earlier detection. The article positions HelioLiver's Quest partnership alongside emerging Phase III immunotherapy trials like IMbrave050 and CARES-009, arguing that improved diagnostics and new treatments together could transform outcomes.